

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 7, 2013

**ACTINIUM PHARMACEUTICALS, INC.**  
(Exact name of registrant as specified in its charter)

<u>Delaware</u> (State or other jurisdiction of incorporation)	<u>000-52446</u> (Commission File Number)	<u>000-52446</u> (IRS Employer Identification No.)
<u>501 Fifth Avenue, 3rd Floor</u> <u>New York, NY</u> (Address of principal executive offices)		<u>10017</u> (Zip Code)

Registrant's telephone number, including area code: **(212) 300-2131**

Actinium Pharmaceuticals, Inc.  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
-

**Item 8.01. Other Events.**

Actinium Pharmaceuticals, Inc., a Delaware company, issued a press release on June 7, 2013 announcing the proceeds received from the exercise of its Series A Warrants. A copy of the press release is attached to this Form 8-K as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits.**

*(d) Exhibits.*

Exhibit 99.1 Press release of Actinium Pharmaceuticals, Inc. dated June 7, 2013.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 7, 2013

**ACTINIUM PHARMACEUTICALS, INC.**

By: /s/ Sergio Traversa

Sergio Traversa  
Interim President, Interim Chief Executive  
Officer, and Interim Chief Financial Officer



Actinium Pharmaceuticals, Inc.

## Actinium Pharmaceuticals, Inc. Receives \$3.5m from Exercise of Warrants

*Actinium Pharmaceuticals receives US \$3,457,087 in proceeds from the exercise of 2,095,204 A-warrants*

**New York, NY, June 7, 2013** -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) announced today the recent issuance of 2,095,204 of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with a private placement that closed in January 2013. The warrants were exercised at US\$ 1.65 per share, resulting in gross proceeds of US\$ 3,457,087 for the Company. As of June 7, 2013 the total number of outstanding common stock is 15,825,394 shares.

"The proceeds from these exercised warrants will be used for the Companies clinical and preclinical programs and for general working capital," said Sergio Traversa, Interim Chief Executive Officer of Actinium Pharmaceuticals. "This capital will allow us to continue to develop our drug candidates for treatment of the most difficult forms of cancer, including Acute Myeloid Leukemia, where they have made significant advances and already helped a number of patients," added Dragan Cicic, MD, Chief Medical Officer of Actinium Pharmaceuticals. "The Company intends to advance its programs into late phases of clinical trials and add new programs by the end of 2013."

Shareholders exercised 2,095,204 (67.2%) of the 3,118,988 originally issued A-warrants.

### **About Actinium Pharmaceuticals**

Actinium Pharmaceuticals, Inc., based in New York, NY, is a biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

### **For more information:**

Visit our web site [www.actiniumpharmaceuticals.com](http://www.actiniumpharmaceuticals.com) or

### **Contact:**

Segio Traversa, CEO

Actinium Pharmaceuticals Inc.

E-mail: [straversa@actiniumpharmaceuticals.com](mailto:straversa@actiniumpharmaceuticals.com)

**Media:**

Dennis S. Dobson Jr.

Tel: (203) 258-0150

E-mail: [dsdobson@optonline.com](mailto:dsdobson@optonline.com)

[www.dobsonmediagroup.com](http://www.dobsonmediagroup.com)

**Forward-Looking Statement for Actinium Pharmaceuticals, Inc.**

This news release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.